Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Dimitrijevic-Sreckovic, V. (6506375884)"

Filter results by typing the first few letters
Now showing 1 - 4 of 4
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    A European evidence-based guideline for the prevention of type 2 diabetes
    (2010)
    Paulweber, B. (36519500600)
    ;
    Valensi, P. (7103187761)
    ;
    Lindström, J. (55646081100)
    ;
    Lalic, N.M. (13702597500)
    ;
    Greaves, C.J. (7005942816)
    ;
    McKee, M. (7202304775)
    ;
    Kissimova-Skarbek, K. (6508376962)
    ;
    Liatis, S. (6602572999)
    ;
    Cosson, E. (6701348575)
    ;
    Szendroedi, J. (6507093621)
    ;
    Sheppard, K.E. (23013221900)
    ;
    Charlesworth, K. (57193097004)
    ;
    Felton, A.-M. (6701433126)
    ;
    Hall, M. (57214475850)
    ;
    Rissanen, A. (36519545100)
    ;
    Tuomilehto, J. (36012823000)
    ;
    Schwarz, P.E. (55356146100)
    ;
    Roden, M. (56289245900)
    ;
    Paulweber, M. (56636735400)
    ;
    Stadlmayr, A. (6507391572)
    ;
    Kedenko, L. (35253673600)
    ;
    Katsilambros, N. (7007026645)
    ;
    Makrilakis, K. (6603246389)
    ;
    Kamenov, Z. (6603678114)
    ;
    Evans, P. (59796388600)
    ;
    Gilis-Januszewska, A. (7801318789)
    ;
    Lalic, K. (13702563300)
    ;
    Jotic, A. (59840631300)
    ;
    Djordevic, P. (36518488100)
    ;
    Dimitrijevic-Sreckovic, V. (6506375884)
    ;
    Hühmer, U. (25724379800)
    ;
    Kulzer, B. (6602515965)
    ;
    Puhl, S. (56974067600)
    ;
    Lee-Barkey, Y.H. (36518998500)
    ;
    Alkerwi, A. (57197724313)
    ;
    Abraham, C. (57197661321)
    ;
    Hardeman, W. (6603849969)
    ;
    Acosta, T. (36518089000)
    ;
    Adler, M. (57213509820)
    ;
    Barengo, N. (6602394675)
    ;
    Barengo, R. (36518110300)
    ;
    Boavida, J.M. (6602950777)
    ;
    Charlesworth, K. (58262841200)
    ;
    Christov, V. (7004530241)
    ;
    Claussen, B. (58382550500)
    ;
    Cos, X. (36518397900)
    ;
    Deceukelier, S. (36518360000)
    ;
    Djordjevic, P. (57200124383)
    ;
    Evans, P. (55732332800)
    ;
    Fischer, M. (59838472700)
    ;
    Gabriel-Sanchez, R. (7103316027)
    ;
    Goldfracht, M. (6507968492)
    ;
    Gomez, J.L. (15047974500)
    ;
    Hall, M. (57197351174)
    ;
    Handke, U. (36518702900)
    ;
    Hauner, H. (55770537200)
    ;
    Herbst, J. (55230674400)
    ;
    Hermanns, N. (6701769664)
    ;
    Herrebrugh, L. (36518612600)
    ;
    Huber, C. (57213336191)
    ;
    Huttunen, J. (7101758583)
    ;
    Kamenov, Z. (35799869900)
    ;
    Karadeniz, S. (36518958700)
    ;
    Khalangot, M. (23028222200)
    ;
    Köhler, D. (35076175100)
    ;
    Kopp, V. (57213281971)
    ;
    Kronsbein, P. (6506721698)
    ;
    Kyne-Grzebalski, D. (56632305700)
    ;
    Landgraf, R. (7102895952)
    ;
    McIntosh, C. (7103076842)
    ;
    Mesquita, A.C. (57198008266)
    ;
    Misina, D. (35269483400)
    ;
    Muylle, F. (56636530800)
    ;
    Neumann, A. (59606721600)
    ;
    Paiva, A.C. (36519360600)
    ;
    Pajunen, P. (55963557800)
    ;
    Peltonen, M. (7004175068)
    ;
    Perrenoud, L. (57226211742)
    ;
    Pfeiffer, A. (22836540000)
    ;
    Pölönen, A. (36519533900)
    ;
    Raposo, F. (36519483800)
    ;
    Reinehr, T. (7003500204)
    ;
    Robinson, C. (14525720400)
    ;
    Rothe, U. (7003825375)
    ;
    Saaristo, T. (16679537200)
    ;
    Scholl, J. (57214610867)
    ;
    Spiers, S. (36519799800)
    ;
    Stemper, T. (36519835600)
    ;
    Stratmann, B. (35235411000)
    ;
    Szybinski, Z. (7006059119)
    ;
    Tankova, T. (8242458100)
    ;
    Telle-Hjellset, V. (57217955971)
    ;
    Terry, G. (36519813900)
    ;
    Tolks, D. (36519979900)
    ;
    Toti, F. (59846967100)
    ;
    Tuomilehto, J. (57217725944)
    ;
    Undeutsch, A. (36519884300)
    ;
    Valadas, C. (36519855100)
    ;
    Velickiene, D. (36519866700)
    ;
    Vermunt, P. (59744379600)
    ;
    Weiss, R. (57225959558)
    ;
    Wens, J. (6602480876)
    ;
    Yilmaz, T. (7006525167)
    Background: The prevalence and socioeconomic burden of type 2 diabetes (T2DM) and associated co-morbidities are rising worldwide. Aims: This guideline provides evidence-based recommendations for preventing T2DM. Methods: A European multidisciplinary consortium systematically reviewed the evidence on the effectiveness of screening and interventions for T2DM prevention using SIGN criteria. Results: Obesity and sedentary lifestyle are the main modifiable risk factors. Age and ethnicity are non-modifiable risk factors. Case-finding should follow a step-wise procedure using risk questionnaires and oral glucose tolerance testing. Persons with impaired glucose tolerance and/or fasting glucose are at high-risk and should be prioritized for intensive intervention. Interventions supporting lifestyle changes delay the onset of T2DM in high-risk adults (number-needed-to-treat: 6.4 over 1.84.6 years). These should be supported by inter-sectoral strategies that create health promoting environments. Sustained body weight reduction by 5% lowers risk. Currently metformin, acarbose and orlistat can be considered as second-line prevention options. The population approach should use organized measures to raise awareness and change lifestyle with specific approaches for adolescents, minorities and disadvantaged people. Interventions promoting lifestyle changes are more effective if they target both diet and physical activity, mobilize social support, involve the planned use of established behaviour change techniques, and provide frequent contacts. Cost-effectiveness analysis should take a societal perspective. Conclusions: Prevention using lifestyle modifications in high-risk individuals is cost-effective and should be embedded in evaluated models of care. Effective prevention plans are predicated upon sustained government initiatives comprising advocacy, community support, fiscal and legislative changes, private sector engagement and continuous media communication. © Georg Thieme Verlag KG Stuttgart - New York.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    A European evidence-based guideline for the prevention of type 2 diabetes
    (2010)
    Paulweber, B. (36519500600)
    ;
    Valensi, P. (7103187761)
    ;
    Lindström, J. (55646081100)
    ;
    Lalic, N.M. (13702597500)
    ;
    Greaves, C.J. (7005942816)
    ;
    McKee, M. (7202304775)
    ;
    Kissimova-Skarbek, K. (6508376962)
    ;
    Liatis, S. (6602572999)
    ;
    Cosson, E. (6701348575)
    ;
    Szendroedi, J. (6507093621)
    ;
    Sheppard, K.E. (23013221900)
    ;
    Charlesworth, K. (57193097004)
    ;
    Felton, A.-M. (6701433126)
    ;
    Hall, M. (57214475850)
    ;
    Rissanen, A. (36519545100)
    ;
    Tuomilehto, J. (36012823000)
    ;
    Schwarz, P.E. (55356146100)
    ;
    Roden, M. (56289245900)
    ;
    Paulweber, M. (56636735400)
    ;
    Stadlmayr, A. (6507391572)
    ;
    Kedenko, L. (35253673600)
    ;
    Katsilambros, N. (7007026645)
    ;
    Makrilakis, K. (6603246389)
    ;
    Kamenov, Z. (6603678114)
    ;
    Evans, P. (59796388600)
    ;
    Gilis-Januszewska, A. (7801318789)
    ;
    Lalic, K. (13702563300)
    ;
    Jotic, A. (59840631300)
    ;
    Djordevic, P. (36518488100)
    ;
    Dimitrijevic-Sreckovic, V. (6506375884)
    ;
    Hühmer, U. (25724379800)
    ;
    Kulzer, B. (6602515965)
    ;
    Puhl, S. (56974067600)
    ;
    Lee-Barkey, Y.H. (36518998500)
    ;
    Alkerwi, A. (57197724313)
    ;
    Abraham, C. (57197661321)
    ;
    Hardeman, W. (6603849969)
    ;
    Acosta, T. (36518089000)
    ;
    Adler, M. (57213509820)
    ;
    Barengo, N. (6602394675)
    ;
    Barengo, R. (36518110300)
    ;
    Boavida, J.M. (6602950777)
    ;
    Charlesworth, K. (58262841200)
    ;
    Christov, V. (7004530241)
    ;
    Claussen, B. (58382550500)
    ;
    Cos, X. (36518397900)
    ;
    Deceukelier, S. (36518360000)
    ;
    Djordjevic, P. (57200124383)
    ;
    Evans, P. (55732332800)
    ;
    Fischer, M. (59838472700)
    ;
    Gabriel-Sanchez, R. (7103316027)
    ;
    Goldfracht, M. (6507968492)
    ;
    Gomez, J.L. (15047974500)
    ;
    Hall, M. (57197351174)
    ;
    Handke, U. (36518702900)
    ;
    Hauner, H. (55770537200)
    ;
    Herbst, J. (55230674400)
    ;
    Hermanns, N. (6701769664)
    ;
    Herrebrugh, L. (36518612600)
    ;
    Huber, C. (57213336191)
    ;
    Huttunen, J. (7101758583)
    ;
    Kamenov, Z. (35799869900)
    ;
    Karadeniz, S. (36518958700)
    ;
    Khalangot, M. (23028222200)
    ;
    Köhler, D. (35076175100)
    ;
    Kopp, V. (57213281971)
    ;
    Kronsbein, P. (6506721698)
    ;
    Kyne-Grzebalski, D. (56632305700)
    ;
    Landgraf, R. (7102895952)
    ;
    McIntosh, C. (7103076842)
    ;
    Mesquita, A.C. (57198008266)
    ;
    Misina, D. (35269483400)
    ;
    Muylle, F. (56636530800)
    ;
    Neumann, A. (59606721600)
    ;
    Paiva, A.C. (36519360600)
    ;
    Pajunen, P. (55963557800)
    ;
    Peltonen, M. (7004175068)
    ;
    Perrenoud, L. (57226211742)
    ;
    Pfeiffer, A. (22836540000)
    ;
    Pölönen, A. (36519533900)
    ;
    Raposo, F. (36519483800)
    ;
    Reinehr, T. (7003500204)
    ;
    Robinson, C. (14525720400)
    ;
    Rothe, U. (7003825375)
    ;
    Saaristo, T. (16679537200)
    ;
    Scholl, J. (57214610867)
    ;
    Spiers, S. (36519799800)
    ;
    Stemper, T. (36519835600)
    ;
    Stratmann, B. (35235411000)
    ;
    Szybinski, Z. (7006059119)
    ;
    Tankova, T. (8242458100)
    ;
    Telle-Hjellset, V. (57217955971)
    ;
    Terry, G. (36519813900)
    ;
    Tolks, D. (36519979900)
    ;
    Toti, F. (59846967100)
    ;
    Tuomilehto, J. (57217725944)
    ;
    Undeutsch, A. (36519884300)
    ;
    Valadas, C. (36519855100)
    ;
    Velickiene, D. (36519866700)
    ;
    Vermunt, P. (59744379600)
    ;
    Weiss, R. (57225959558)
    ;
    Wens, J. (6602480876)
    ;
    Yilmaz, T. (7006525167)
    Background: The prevalence and socioeconomic burden of type 2 diabetes (T2DM) and associated co-morbidities are rising worldwide. Aims: This guideline provides evidence-based recommendations for preventing T2DM. Methods: A European multidisciplinary consortium systematically reviewed the evidence on the effectiveness of screening and interventions for T2DM prevention using SIGN criteria. Results: Obesity and sedentary lifestyle are the main modifiable risk factors. Age and ethnicity are non-modifiable risk factors. Case-finding should follow a step-wise procedure using risk questionnaires and oral glucose tolerance testing. Persons with impaired glucose tolerance and/or fasting glucose are at high-risk and should be prioritized for intensive intervention. Interventions supporting lifestyle changes delay the onset of T2DM in high-risk adults (number-needed-to-treat: 6.4 over 1.84.6 years). These should be supported by inter-sectoral strategies that create health promoting environments. Sustained body weight reduction by 5% lowers risk. Currently metformin, acarbose and orlistat can be considered as second-line prevention options. The population approach should use organized measures to raise awareness and change lifestyle with specific approaches for adolescents, minorities and disadvantaged people. Interventions promoting lifestyle changes are more effective if they target both diet and physical activity, mobilize social support, involve the planned use of established behaviour change techniques, and provide frequent contacts. Cost-effectiveness analysis should take a societal perspective. Conclusions: Prevention using lifestyle modifications in high-risk individuals is cost-effective and should be embedded in evaluated models of care. Effective prevention plans are predicated upon sustained government initiatives comprising advocacy, community support, fiscal and legislative changes, private sector engagement and continuous media communication. © Georg Thieme Verlag KG Stuttgart - New York.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    siMS score- method for quantification of metabolic syndrome, confirms co-founding factors of metabolic syndrome
    (2023)
    Dimitrijevic-Sreckovic, V. (6506375884)
    ;
    Petrovic, H. (57222276058)
    ;
    Dobrosavljevic, D. (21133925200)
    ;
    Colak, E. (56216778500)
    ;
    Ivanovic, N. (23097433900)
    ;
    Gostiljac, D. (13409402200)
    ;
    Ilic, S. (57212487618)
    ;
    Nikolic, D. (55149192700)
    ;
    Gacic, J. (26023073400)
    ;
    Soldatovic, I. (35389846900)
    Background: Adipose tissue is a dynamic endocrine organ, a highly active metabolic tissue, and an important source of cytokines. Inflammatory factors play an important role in visceral obesity associated with insulin resistance (IR), metabolic syndrome (MS), hypertension, non-alcoholic fatty liver disease (NAFLD), diabetes mellitus type 2 (DM2), endothelial dysfunction (ED) and atherosclerosis. Objectives: To examine corelation of siMS score, as a quantification method for metabolic syndrome (MS), with insulin resistance, glucoregulation parameters, as with other co-founding factors of MS, inflammation and thrombosis factors, microalbuminuria, uric acid, fatty liver index (FLI) and homocysteine. Methods: The study included 451 obese individuals with pre–metabolic syndrome (pre-MS) and MS (age 16–75, body mass index (BMI) > 25kg/m2) classified into two groups: I-age 10–30 (167 patients); II-age 31–75 (284 patients). International Diabetes Federation (IDF) classification was applied for diagnosing metabolic syndrome. Patients with less than three criteria indicated below were considered pre-metabolic syndrome. siMS risk score was used. Results: siMS score increased with age: I-3.03 ± 0.87, II-3.27 ± 0.90. siMS score correlated with associated factors of MS: hyperinsulinemia and IR, ALT, gama-GT, FLI, uric acid in both groups and CRP (p < 0.01) in group I. Correlations in II group: siMS score with PAI-1 (p = 0.01), microalbuminuria (p = 0.006), homocysteine ​​(p = 0.076). Conclusion: Correlation of siMS score with HOMA-IR confirmed that hyperinsulinism and insulin resistance are in the basis of MS. Correlation of siMS score with parameters of NAFLD, CRP, PAI-1, uric acid, microalbuminuria and homocysteine indicates that they are significant co-founding factors of MS. Correlation of siMS score with PAI-1, microalbuminuria, homocysteine, indicates higher risk for progression of endothelial dysfunction and atherosclerosis with age. Copyright © 2023 Dimitrijevic-Sreckovic, Petrovic, Dobrosavljevic, Colak, Ivanovic, Gostiljac, Ilic, Nikolic, Gacic and Soldatovic.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    siMS score- method for quantification of metabolic syndrome, confirms co-founding factors of metabolic syndrome
    (2023)
    Dimitrijevic-Sreckovic, V. (6506375884)
    ;
    Petrovic, H. (57222276058)
    ;
    Dobrosavljevic, D. (21133925200)
    ;
    Colak, E. (56216778500)
    ;
    Ivanovic, N. (23097433900)
    ;
    Gostiljac, D. (13409402200)
    ;
    Ilic, S. (57212487618)
    ;
    Nikolic, D. (55149192700)
    ;
    Gacic, J. (26023073400)
    ;
    Soldatovic, I. (35389846900)
    Background: Adipose tissue is a dynamic endocrine organ, a highly active metabolic tissue, and an important source of cytokines. Inflammatory factors play an important role in visceral obesity associated with insulin resistance (IR), metabolic syndrome (MS), hypertension, non-alcoholic fatty liver disease (NAFLD), diabetes mellitus type 2 (DM2), endothelial dysfunction (ED) and atherosclerosis. Objectives: To examine corelation of siMS score, as a quantification method for metabolic syndrome (MS), with insulin resistance, glucoregulation parameters, as with other co-founding factors of MS, inflammation and thrombosis factors, microalbuminuria, uric acid, fatty liver index (FLI) and homocysteine. Methods: The study included 451 obese individuals with pre–metabolic syndrome (pre-MS) and MS (age 16–75, body mass index (BMI) > 25kg/m2) classified into two groups: I-age 10–30 (167 patients); II-age 31–75 (284 patients). International Diabetes Federation (IDF) classification was applied for diagnosing metabolic syndrome. Patients with less than three criteria indicated below were considered pre-metabolic syndrome. siMS risk score was used. Results: siMS score increased with age: I-3.03 ± 0.87, II-3.27 ± 0.90. siMS score correlated with associated factors of MS: hyperinsulinemia and IR, ALT, gama-GT, FLI, uric acid in both groups and CRP (p < 0.01) in group I. Correlations in II group: siMS score with PAI-1 (p = 0.01), microalbuminuria (p = 0.006), homocysteine ​​(p = 0.076). Conclusion: Correlation of siMS score with HOMA-IR confirmed that hyperinsulinism and insulin resistance are in the basis of MS. Correlation of siMS score with parameters of NAFLD, CRP, PAI-1, uric acid, microalbuminuria and homocysteine indicates that they are significant co-founding factors of MS. Correlation of siMS score with PAI-1, microalbuminuria, homocysteine, indicates higher risk for progression of endothelial dysfunction and atherosclerosis with age. Copyright © 2023 Dimitrijevic-Sreckovic, Petrovic, Dobrosavljevic, Colak, Ivanovic, Gostiljac, Ilic, Nikolic, Gacic and Soldatovic.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback